We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Test for Blood Volume Analysis

By LabMedica International staff writers
Posted on 27 May 2022

Implantable left ventricular assist devices have dramatically changed the face of advanced heart failure treatment and constitute a USD 350 million annual market in the US. More...

Patients suffering from persistent blood volume derangements have lower survival and decreased with left ventricular assist device (LVAD) functionality but go largely undiagnosed. Accurate quantification of total blood volume, plasma volume, and red blood cell volume analysis can inform physicians, leading to better treatment strategies and better patient outcomes. Now, the first diagnostic blood test cleared by the FDA provides safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

Daxor Corporation’s (Oak Ridge, TN, USA) BVA-100 (Blood Volume Analyzer) provides clinicians with accurate, actionable data to optimize treatment plans and individualize care improving outcomes and reducing duration and cost of care. It directly quantifies the intravascular blood, plasma and red cell giving actionable information needed to achieve optimal fluid management. The BVA-100 quantifies circulating blood volume utilizing the gold standard methodology, the indicator tracer dilution technique. The test is administered at the bedside, blood samples are drawn and sent to the laboratory for processing. Preliminary data is available within 30 minutes to help guide decisions in emergency situations.

Over 100 published peer-reviewed studies across many medical conditions have proven the BVA-100’s unique safety, accuracy, efficacy, and value. New data has validated the benefits of BVA-100 in improving survival for advanced heart failure patients with LVAD. The study describes variations in blood volume status (total blood and red blood cell volume) in 45 stable ambulatory patients with LVAD. Blood volume parameters were measured with the BVA-100 diagnostic blood test, which is a safe, 98% accurate, and objective test to directly quantify blood volume and composition. The study concluded that plasma volume abnormality was found in 75% of patients. The data revealed that only 9% of these patients had normal blood volume results; 54% had significant red blood cell deficit and 12% had red blood cell excess.

“This research reinforces that a volume-guided approach in treating advanced heart failure with the BVA-100 blood test is paramount in informing the correct treatment strategies - resulting in significantly better clinical benefits and survival for patients,” said Michael Feldschuh, President, and CEO of Daxor Corporation.

Related Links:
Daxor Corporation 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Chemistry System
P780
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.